Third drug signed off for early access in France
This article was originally published in SRA
Executive Summary
Johnson & Johnson/MSD's Remicade (infliximab) is to be made available to French patients for the unapproved indication of Takayasu's arteritis refractory to conventional drugs, under a temporary use recommendation (RTU)1. Remicade is the third drug to be granted an RTU, a relatively new early-access mechanism, in France.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.